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patient satisfaction and cost-effectiveness
of a reduced follow-up schedule: study
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Abstract
Background: It has often been hypothesized that the frequency of follow-up visits for patients with early-stage
endometrial cancer could be decreased. However, studies evaluating effects of a reduced follow-up schedule
among this patient group are lacking. The aim of this study is to assess patient satisfaction and cost-effectiveness of
a less frequent follow-up schedule compared to the schedule according to the Dutch guideline.
Methods: In this multicenter randomized controlled trial, patients diagnosed in the Netherlands with stage 1A and
1B low-risk endometrial cancer, for whom adjuvant radiotherapy is not indicated (n = 282), are randomized. Patients
allocated to the intervention group receive four follow-up visits during three years. Patients allocated to the control
group receive 10–13 follow-up visits during five years, according to the Dutch guideline. Patients are asked to fill
out a questionnaire at baseline and after 6, 12, 36, and 60 months. Primary outcomes include patient satisfaction
with follow-up care and cost-effectiveness. Secondary outcomes include healthcare use, adherence to schedule,
health-related quality of life, fear of recurrence, anxiety and depression, information provision, recurrence, and
survival. Linear regression analyses will be used to assess differences in patient satisfaction with follow-up care
between intervention and control group.
Discussion: We anticipate that patients in the intervention arm have a similar satisfaction with follow-up care and
overall outcomes, but lower healthcare use and costs than patients in the control arm. No differences are expected
in quality-adjusted life-years and satisfaction, but the reduced schedule is expected to be cost-saving when
implemented in the Netherlands.
Trial registration: ClinicalTrials.gov, NCT02413606. Registered on 10 April 2015.
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Patient-reported outcomes, Satisfaction with care, Cost-effectiveness
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Background
Endometrial cancer is the most common gynecological
cancer, with about 1900 newly diagnosed patients per
year in the Netherlands. Today, about 20,000 women liv-
ing in the Netherlands have survived endometrial cancer,
of whom almost 8000 were diagnosed in the past
five years and are currently receiving follow-up care [1].
Women with early-stage cancer (55%) with favorable
features receive surgery only, while those with risk fac-
tors or with more advanced stages generally receive ad-
juvant radiotherapy [2]. Most patients are followed after
treatment for five years according to the current guide-
line, with hospital visits every three or four months in
the first two years after treatment, every 4–6 months in
the third year, and annually in the fourth and fifth years.
Reasons for follow-up include early diagnosis of recur-
rences—for which curative treatment is available, signal-
ing and treating adverse events of cancer and treatment,
psychosocial support, and information provision [3, 4].
The optimal follow-up schedule for patients with
endometrial cancer is unknown [4–8]. As a result, guide-
lines in the Netherlands are consensus-based and do not
take risk profile into account. Due to current emphasis
on providing high-quality care at lower costs, a critical
evaluation of current follow-up practices for cancer
patients is needed [9–11]. The transition of follow-up
care to the nurse specialist [12, 13] or primary care
physician [14, 15] has been presented as a means to
increase the cost-effectiveness of follow-up care.
However, reduction of the frequency and duration of
follow-up visits has not yet been evaluated [4, 10].
Current evidence provides a multitude of reasons that
support reduction of standard follow-up visits. First,
there is no survival benefit in the detection of asymp-
tomatic recurrences at routine follow-up, compared with
symptomatic recurrence or interval detection [4, 5, 8,
16–18], probably because the recurrence rate of early-
stage endometrial cancer survivors is low (3%) and
because most recurrences (70%) present with symptoms
[5]. The majority (70–100%) of the recurrences occur
within three years [5]. Second, side-effects from
treatments are found in only 6% of the stage 1 patients
who received surgery (hysterectomy and salpingo-
oophorectomy) alone [2, 19]. Third, follow-up visits evoke
distress around the time of the visits [15, 17, 20–22].
Finally, alternative follow-up schedules in other can-
cer populations do not show decreased patient
satisfaction or health-related quality of life (HRQoL)
[23, 24]. At the same time, there are reasons to retain
some follow-up care, including that follow-up is bene-
ficial for patients for reassurance [15, 21, 25], to pro-
vide support for psychosocial, physical, and sexual
problems [2, 3, 24], and to provide information [26]
and tertiary prevention care [27].
These findings suggest that most early-stage endomet-
rial cancer patients do not need intensive follow-up to
detect recurrences, improve survival, or discuss conse-
quences of treatment. However, patients may need some
follow-up to detect information needs and provide psy-
chosocial counseling. Therefore, a reduced follow-up
schedule for low-risk, early-stage endometrial cancer pa-
tients should focus on eliminating unnecessary care,
which is expected to result in decreased patient worry
around visits, prevent wrong patient expectations, and
save healthcare costs. At the same time, a minimal num-
ber of follow-up visits is needed to support necessary
patient counseling and information provision [8–10].
Additionally, it is increasingly recognized that cancer
survivors should be provided with information about
their disease, treatment, care providers, physical and
psychosocial consequences of their cancer and its treat-
ment, care services, and health promotion information
[28, 29]. The Institute of Medicine recommends the use
of Survivorship Care Plans to provide cancer survivors
this information [28]. Although Survivorship Care Plans
did not increase satisfaction with information provision
and care among gynecological cancer patients [30, 31],
they may support symptom monitoring. Adequate moni-
toring of symptoms by patients would enhance early
detection of symptomatic recurrences while limiting the
need for follow-up visits.
To obtain evidence on the effects of a reduced follow-
up schedule we propose to conduct a nationwide
randomized controlled trial (RCT) to study the effects of
a reduced follow-up schedule for patients with endomet-
rial cancer. We hypothesized that the patients in the
intervention group report at least similar levels of
patients’ satisfaction with care at lower costs.
Methods/Design
Objectives and hypotheses
The aim of this study is to compare a reduced follow-up
schedule of four visits in three years among low-risk,
early-stage endometrial cancer survivors, with the sched-
ule according to the current Dutch guideline that
includes 10–13 visits in five years. Primary outcomes in-
clude patient satisfaction with follow-up care and costs-
effectiveness from the healthcare perspective. Secondary
outcomes include healthcare use, adherence to the indi-
cated follow-up protocols, reasons for non-adherence,
HRQoL, worry including fear of recurrence, anxiety and
depression, satisfaction with information provision,
healthcare providers’ satisfaction with follow-up sched-
ule, time till recurrence, and survival.
We hypothesize that endometrial cancer patients in
the intervention arm of the study are not less satisfied
with the follow-up care and do not report worse
HRQoL, fear of recurrence, anxiety, depression, and
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information provision satisfaction. We furthermore
hypothesize that healthcare use and associated costs will
be lower in the intervention arm, resulting in a cost-
effective intervention. More precisely, we expect that by
reducing the follow-up schedule from 10–13 to four
visits, the costs of these visits will be saved, although
some substitution might occur to care by the specialist,
specialized nurse, or general practitioner. From a health-
care perspective, we expect this alternative follow-up
schedule will save costs.
Design
A national multicenter (non-inferiority) RCT among 282
endometrial cancer survivors will be conducted. Patients
will be randomized 1:1 in the intervention or control
group. Since differences in outcomes between groups
are expected to be most pronounced within the first
three years of follow-up and the largest cost-saving is
achieved within three years, we will evaluate this study
in a two-step approach, with an evaluation after one,
three, and five years. After five years, the follow-up
according to the guideline ends. Patients in both arms
receive a Survivorship Care Plan, with information on
symptoms which would necessitate a consultation.
Doctors and patients cannot be blinded for interven-
tion or control group assignment. A questionnaire will
be sent to all patients at baseline (after primary treat-
ment), and 6, 12, 36, and 60 months later. The baseline
questionnaire will be assessed before the intervention
under study, that is the different follow-up schedules,
starts. Healthcare use, recurrences, survival, and costs
will be assessed after three and five years. A schedule of
the study is presented in Fig. 1. Healthcare professionals
will receive a questionnaire at the end of the study. In
addition, a non-participation study will be performed
registering hospital healthcare use and assessing patient-
reported outcomes using a questionnaire. Medical Ethics
approval will be obtained before the start of this project.
Setting
Hospitals throughout the Netherlands can participate. In
total, 46 centers (both academic and non-academic
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centers) will include patients. Participating centers are
listed at http://www.ClinicalTrials.gov. Inclusion will
take approximately 2.5 years.
Study population
Low-risk, early-stage endometrial cancer survivors who
receive no adjuvant (radio)therapy after initial surgery
will be included in the study.
Inclusion criteria
Patients with endometrioid type endometrial carcinoma
with stage 1 (FIGO, 2009) low-risk disease, with the fol-
lowing combination of stage, age, and grade will be eli-
gible: (1) stage 1A, any age, grade 1 or 2; or (2) stage 1B,
< 60 years, grade 1 or 2 without lymphovascular space
invasion (LVSI). Other inclusion criteria are written in-
formed consent and sufficient oral and written com-
mand of the Dutch language. Tumor stage, grade, and
type should be histological confirmed by the pathologist
before inclusion.
Exclusion criteria
Exclusion criteria include: (1) any other stage and type
of endometrial carcinoma; (2) histological types papillary
serous carcinoma or clear cell carcinoma; (3) uterine
sarcoma (including carcinosarcoma); (4) receive radio-
therapy for current endometrial carcinoma; (5) previous
malignancy (except for non-melanomatous skin cancer)
< 5 years; (6) having metastases of other tumors; (7) con-
firmed Lynch syndrome; and (8) previous pelvic
radiotherapy.
Recruitment
The national Trial Office of the Netherlands Compre-
hensive Cancer Organization (IKNL) will organize data
collection. Patient-reported outcomes will be obtained
by questionnaires [32]. Informed consent will be asked
by the treating gynecologist during the postoperative
visit. The patient is provided information about the
study and an informed consent form. Patients have 2–
4 weeks to consider the proposal and can ask questions
for instance during an extra visit or a telephone call. In
the visit 5–7 weeks after diagnosis, the patient signs the
written informed consent and provides address informa-
tion, in case she is willing to participate. The
gynecologist fills out the Randomization Form and sends
it to the IKNL Trial Office, who performs the
randomization. The patient receives the paper question-
naire and a pre-stamped envelope, to be completed at
home. The patients send the completed questionnaire to
the IKNL Trial Office. At 6, 12, 36, and 36 months the
participant will receive a questionnaire plus pre-stamped
envelope at their home address. Non-respondents will
be sent a reminder letter and questionnaire within six
weeks. Only for the baseline questionnaire will this pro-
cedure will be faster to assure a proper baseline measure
(reminder through the local principal investigator or re-
search nurse after two weeks). If the patient moves to
another hospital, a form will be used to obtain patient
data from the new hospital. If the patient does not want
to participate in the trial, she is still asked to fill out a
single questionnaire and consent to assess healthcare
use information, allowing the researchers to compare
participants and non-participants. If the patient agrees,
the gynecologist completes the registration form for
non-participants and sends it to the IKNL Trial Office.
The gynecologist provides the patients with a set includ-
ing a short one-time questionnaire, an informed consent
form to assess healthcare use data and a pre-stamped
envelope. No other data will be collected for this patient.
Questionnaires will be scanned and the database will be
checked for a sample of ten patients. On the total data-
base, range and consistency checks will be conducted.
Clinical research forms (CRF) will be completed directly
in a program.
Randomization
Patients are randomized via a randomization program,
using a computer-generated list of random numbers.
Block randomization will be used (no stratification) to as-
sure approximately equal numbers in both groups. Con-
cealment of randomization allocation is guaranteed by the
fact that only after written informed consent, the trial
manager obtains the randomization allocation from the
randomization program and sends it to the gynecologist.
Intervention versus usual care
Usual care
The control group receives follow-up care according to
Dutch guideline [2] . This guideline proposes follow-up
visits every 3–4 months during the first and second
years, every 4–6 months during the third year, and every
12 months during the fourth and fifth years after the
end of treatment irrespective of stage and grade [2],
resulting in a total of 10–13 visits in five years.
Intervention
In the intervention group, the follow-up schedule will be
limited to four follow-up visits at 3, 12, 24, and 36 months,
under the specific condition that patients have easy and
prompt access to care (specialized nurse of gynecologist)
if symptoms or questions occur. The content of the
follow-up visits will be similar for both groups. In both
arms a Survivorship Care Plan, including signs of recur-
rence, will be provided [33]. This Survivorship Care Plan
is personalized based on information that is completed in
the randomization form and is emailed as a pdf file to the
patient’s caregivers upon randomization.
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Patient and medical outcomes
During the study the following outcomes will be
assessed using clinical research forms.
Patient-related outcomes include date of birth, other
malignancies during the past five years, WHO perform-
ance status, weight, height, co-morbidity, menopausal
status
Conduct of preoperative investigations, including CT
or X-ray of the chest, CT or MRI of the abdomen and
pelvis, and Ca-125.
Surgery-related measures include date of surgery, date
of hospital discharge, type of surgery, blood loss, transfu-
sion, complications of surgery, if the patients were in in-
tensive or medium care, if there was a re-intervention
for complications
Pathology investigations include histology, FIGO stage,
FIGO grade, size of the tumor, myometrial invasion,
minimal distance between the tumor and the serosa,
LVSI.
Follow-up measures include date of follow-up visit, be-
ing a regular or extra visit, performance status, disease
status, healthcare use (gynecologist, oncology nurse), in-
vestigations (CT or X-ray of the chest, CT or MRI of the
abdomen and pelvis, PET scan, echo, Ca-125)
Recurrence measures include symptomatic/asymptom-
atic recurrence, localization, date, and new treatment.
End of study measures include date lost to follow-up,
reasons loss to follow-up, and date and cause of death.
Healthcare use comprises consults with the specialist,
the (specialist) nurse, and the primary care physician,
hospital admissions, length of hospital stay, and diagnos-
tics (X-ray, CT, MRI, PET scans, echo, Ca-125).
Cost-prices will be obtained from guideline on cost
research from the CVZ [34].
Patient-reported outcomes
We will use existing validated instruments to measure
the patient reported outcomes that we hypothesized to
be affected by the follow-up visits.
Patient satisfaction with follow-up care will be assessed
using the Dutch version of the Patient Satisfaction Ques-
tionnaire III of which the psychometrics have been
assessed in a Dutch oncologic sample [35]. This includes
three aspects of healthcare: technical competence (ten
items); interpersonal aspects (14 items); and access to
care (12 items). The questionnaire can be used as a one-
dimensional model, which will be used as the main out-
come (PSQ total score).
Overall quality of life will be assessed using the EQ-5D
[36], a standardized instrument which provides a de-
scriptive profile and a single index value for health sta-
tus. The measure will be used for the economic
evaluation, as it can be used to compute QALYs.
Cancer-specific HRQoL will be measured using the
EORTC-QLQ-C30 [37]. Much of the content of the
questionnaire is appropriate for extended monitoring of
health status, including scales assessing physical, role,
cognitive and emotional functioning, fatigue and sleep
problems, and overall health and QoL.
Tumour-specific complaints will be measured using a
condition-specific supplement, the EORTC-QLQ-EN24
[25]. The module assesses lymphedema, urological
symptoms, gastrointestinal symptoms, body image, sex-
ual/vaginal symptoms, back/pelvic pain, and chemother-
apy side effects.
Worry, including fear of recurrence, will be assessed
using a module from the validated IOCv2 [38] question-
naire. The module consists of six questions including
items about worry about the future, worry about health
because of the cancer, and worry about a recurrence.
This module is a concise measure to assess fear of recur-
rence and worry.
Anxiety and depression will be assessed using the
Hospital Anxiety and Depression Scale (HADS), an often
used and validated scale in this population [39, 40].
Satisfaction with information will be measured using
the EORTC-INFO25 module [41]. This questionnaire
aims to evaluate the (satisfaction with) information
received by cancer patients on different areas of the dis-
ease, diagnosis, treatment, and care. The questionnaire
contains the following scales: (1) information about the
disease; (2) information about medical tests; (3) informa-
tion about treatment; (4) information about other ser-
vices—and the following single items: (1) written
information; (2) information on CD or tape/video; (3)
satisfaction with the amount of information; (4) desire
for more information; (5) desire for less information;
and (6) helpfulness of information.
Healthcare use will also be assessed by asking the fre-
quency of contact with the primary care physician and
medical specialist. We will also ask the patient how often
these visits were related to cancer. In addition, we will as-
sess how often the patients used additional care services
(e.g. psychologist, rehabilitation course, physiologist).
Co-morbidities at the time of questionnaire completion
will be measured using the Self-administered Comorbidity
Questionnaire (SCQ) [42]. Patients will be asked to iden-
tify co-morbid conditions developed in the past 12 months.
The adapted SCQ lists 14 medical conditions (with the
option to list up to three additional conditions).
Additional measures include demographic and socio-
economic variables such as age, education, marital
status, and employment status.
Non-participation evaluation
Patients who do not want to participate in the trial are
asked to complete a single questionnaire. Questions
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include demographics, worry (including fear of recur-
rence), illness perceptions, and satisfaction with care.
For patients who provide informed consent to assess
healthcare use, hospital healthcare use (number of visits
to the gynecologist and the specialized nurse) will be
registered.
Healthcare provider evaluation
Since the satisfaction of the healthcare provider is also
of interest in this project, we will assess the satisfaction
of the specialists with the follow-up schemes using a
short questionnaire.
Sample size
The power calculation is performed on the first primary
outcome “satisfaction with follow-up care.” The maximal
difference between the groups that we find acceptable
(non-inferiority margin) is 6 points (< 0.5 SD) on a scale
from 0 to 100, with a standard deviation (SD) of 14.3 by
[35], based on the rule of thumb as supposed for the
EORTC_QLQ-C30 questionnaire [43]. Therefore, with
alpha 0.05 and beta 0.80 we need a sample size of 180
(90 per study arm). In this sample size we assume that
30–50 centers will participate and as a consequence we
adjusted the number needed in the analysis to account
for the clustering of patients within hospitals. With an
expected loss to follow-up of 20% and patient who die
(16%) over five-year follow-up we need to include 282
patients. Assuming that 60% of the patients will partici-
pate, we need 470 eligible patients. In the Netherlands,
450 patients per year meet the inclusion criteria. Since
not all hospitals will start inclusion at the same time, we
expect an inclusion period of 2.5 years.
Statistical analysis
Data will be analyzed after one, three, and five years of
follow-up. All patients will be included in the analyses
and all patients will be analyzed according to the arm to
which they were assigned (intention-to-treat). In
addition, per protocol analyses will be conducted includ-
ing patients who received follow-up care as intended in
the trial arms. Intention-to-treat and per-protocol ana-
lyses are both important in non-inferiority trials. Data
will be analyzed using descriptive statistics, linear, and
logistic regression analyses. Primary outcome is satisfac-
tion with follow-up care over three-year follow-up. The
primary outcome will be analyzed one-sided. Secondary
outcomes will also be analyzed as non-inferiority using
0.5 SD as a non-inferiority margin, but will be tested
two-sided.
Multilevel multivariate linear and logistic regression
analyses will be conducted for continuous and dichot-
omous outcomes, respectively. Analyses will include
relevant pre-defined covariates to improve the power.
Differential effects by fear of recurrence will be evalu-
ated by adding the interaction term (group*moderator)
to the model. We will carry out repeated measures ana-
lyses using multilevel linear mixed models, which ac-
counts for the intra-patient dependency of the repeated
measures. Missing outcomes will be assumed missing at
random (MAR). An advantage of multilevel linear mixed
models is that all patients can be included in the ana-
lyses, regardless of whether they have been missing some
follow-up measurements. All tests will be considered
significant if p < 0.05. Clinically meaningful differences
will be determined with Norman’s “rule of thumb,”
whereby a difference of > 0.5 SD indicates a threshold of
discriminant change in health status scores of a chronic
illness [43]. If we have the baseline data of a patient, we
will include this patient in the analysis.
The cost-effectiveness analysis will be performed from
a healthcare perspective with a time horizon of
36 months and will be expressed as the incremental cost
per QALYs (based on the EQ-5D) and the incremental
costs per satisfied patient. Based on results up to
36 months, five-year cost-effectiveness results will be
estimated. Patient adherence to the reduced follow-up
schedule will explicitly be addressed in the cost-
effectiveness analysis. A budget impact analysis will be
performed according to the ISPOR guidelines [44]. The
budget impact analysis addresses the financial stream of
consequences related to the implementation of and
compliance with the reduced follow-up scheme to assess
affordability. The budget impact will depend on both the
cost-savings due to reduced follow-up visits, the uptake
by specialists, adherence of patients as well as potential
cost increases, e.g. at the level of the primary care
physician.
Results of the trial will be published in scientific jour-
nals and communicated to the patients via patient
organizations.
Discussion
Although the current guidelines in the Netherlands de-
scribe five years of hospital-based follow-up for women
after their treatment for endometrial cancer, hardly any
scientific evidence exists to support this timely and
expensive practice which involves increasing resources
due to the growing number of cancer survivors. There-
fore, a critical evaluation of follow-up care for endomet-
rial cancer survivors is needed. The current landscape of
evidence predominantly focuses on transitioning follow-
up care to nurses or primary care physicians [45].
However, we hypothesize that reducing the frequency of
follow-up care would result in a higher cost-effectiveness
through retaining levels of satisfaction and outcomes,
while decreasing the costs of follow-up care. Outcomes
of our trial may therefore evoke a new framing of the
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issue of follow-up care, by shifting the focus from transi-
tioning care to eliminating unnecessary care, without
disregarding a minimal level of follow-up care that is
needed to provide adequate information, psychosocial
support, and tertiary prevention [15, 21, 25]. Although
Survivorship Care Plans did not increase satisfaction
with information and care in a previous trial [30, 31], we
expect that Survivorship Care Plans support symptom
monitoring, thereby limiting the need for additional
follow-up visits to detect symptomatic recurrences.
Patients who do not agree to participate in the trial
may have higher needs regarding follow-up care and, for
instance, higher levels of psychological distress. If our
non-participation study shows differences between par-
ticipants and non-participants, the results of the study
may not be generalizable to the full population of inter-
est. In light of this potential result, individualized follow-
up care may be a viable solution, by tailoring the num-
ber of follow-up visits based on patient preferences and
(clinical) characteristics. On the other hand, if partici-
pants of the trial seem representative of the target popu-
lation and a reduced follow-up schedule results in a
similar patient satisfaction at lower costs, the current
guideline will be adapted and the reduced schedule will
be implemented throughout the Netherlands. Further-
more, a reduced follow-up schedule may be applicable
to other cancer types and practices outside of the
Netherlands.
Other trials in this field that have been published,
including the ENDCAT trial, focus on transitions to
(nurse-led) telephone follow-up [12, 13]. Ongoing trials
include OPAL, TOPCAT-G, and TOTEM [4]. Similar to
ENSURE, OPAL (trial number NCT01853865) is com-
paring a reduced patient-initiated follow-up compared to
standard care and restricted recruitment to low- and
intermediate-risk endometrial cancer. TOPCAT-G (trial
number ISRCTN45565436) assesses a reduced regime of
nurse-led telephone follow-up and includes non-
endometrial gynecological cancers but excludes sarco-
mas and trophoblastic tumors. Unlike others, TOTEM
(trial number NCT00916708) has an active arm for
more intense follow-up and is uniquely powered to com-
pare survival among endometrial cancer patients.
In conclusion, the ENSURE trial will provide new in-
sights into the (cost-)effectiveness of a reduced follow-
up schedule in low-risk endometrial cancer patients and
will guide future recommendations for evidence-based
follow-up. Results will show whether patients are willing
to participate in the trial and thus agree on reduced
follow-up. In addition, the non-participation study will
provide insight why some patients do not agree to be
randomized in one of both study arms. If reduced
follow-up results in similar levels of satisfaction and out-
comes at lower costs, a reduced schedule can become
part of regular follow-up care for early-stage endometrial
cancer patients.
Trial status
At the time of manuscript submission, the trial was open
for patient inclusion. Additional information on the trial
can be found in Additional files 1 and 2.
Additional file
Additional file 1: Table WHO Trial Registration Data Set (TRDS) and
additional protocol information of the ENSURE trial. (DOCX 50 kb)
Additional file 2: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 121 kb)
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